Medtronic, one of the largest manufacturers of insulin pumps and continuous glucose monitors, issued a call to action request for insurance companies. The need for greater coverage on continuous glucose monitors is as important (and as necessary) as the rising demand for insulin pumps.

The president of Medtronic's diabetes division, Chris O'Connell, urged the insurance companies to consider the vast growth of the company - which was measured as considerably faster than the industry average, with sales climbing 24% in the last quarter. The device was approved for adult patients last year and U.S. regulators approved an expanded edition for use in children. The continuous glucose monitor alerts diabetics to dangerous spikes or dips in their blood sugar levels via wire-like sensors inserted under the skin that measure glucose levels and transmit the data wirelessly to a pager-size receiver.

The company plans to conduct clinical studies to demonstrate the cost effectiveness of the technology. Presumably, after two to three years of clinical trials, the evidence will be conclusive enough for insurance companies to consent to providing greater coverage for this continuous glucose monitoring.